Adenosine for myocardial protection in acute myocardial infarction

American Journal of Cardiology

Volumn 79, Issue 12 A, 1997, Pages 44-48

  Granger, Christopher B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; FLUOSOL; LIDOCAINE; MAGNESIUM; METOPROLOL; PROSTACYCLIN; TRIMETAZIDINE;

ACUTE HEART INFARCTION; ANGIOPLASTY; CLINICAL TRIAL; CONFERENCE PAPER; CORONARY ARTERY BYPASS GRAFT; FIBRINOLYTIC THERAPY; HEART INFARCTION SIZE; HEART PROTECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REPERFUSION INJURY;

ADENOSINE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; CARDIOVASCULAR AGENTS; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; RANDOMIZED CONTROLLED TRIALS; THROMBOLYTIC THERAPY; VASODILATOR AGENTS;

EID: 0030871604     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(97)00263-4     Document Type: Conference Paper

References (55)

1. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1,000 patients. Lancet. 343:1994;311-322.
2. Simes RJ, Weaver DW, Ellis SG, Grines CL. Overview of the randomized trials of primary PTCA and thrombolysis in acute myocardial infarction. Circulation. 94:((suppl I)):1996;I-330.
3. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death: 1. Myocardial infarct size versus duration of coronary occlusion in dogs. Circulation. 56:1997;786-794.
4. Simes RJ, Topol EJ, Holmes DR, White HD, Rutsch WR, Vahanian A, Simoons ML, Morris D, Betriu A, Califf RM, Ross AM. GUSTO-I investigators. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. Circulation. 91:1995;1923-1928.
5. Kloner RA, Ganote CE, Jennings RB. The "no-reflow" phenomenon following temporary coronary occlusion in the dog. J Clin Invest. 54:1974;1496-1508.
6. Sommers HM, Jennings RB. Experimental acute myocardial infarction: histologic and histochemical studies of early myocardial infarcts induced by temporary or permanent occlusion of a coronary artery. Lab Invest. 13:1964;1491-1502.
7. Kloner RA. Does reperfusion injury exist in humans. J Am Coll Cardiol. 21:1993;537-545.
8. Jolly SR, Kane WF, Bailie MB, Abrams GD, Lucchesi BR. Canine myocardial reperfusion injury: its reduction by the combined administration of superoxide dismutase and catalase. Circ Res. 54:1984;277-285.
9. Free radicals, reperfusion and myocardial infarction therapy: European Myocardial Infarction Project - free radicals pilot study. Eur Heart J. 14:((suppl G)):1994;48-51.
10. Kloner RA, Braunwald E. Effects of calcium antagonists on infarcting myocardium. Am J Cardiol. 59:((suppl)):1987;84B-94B.
11. Hammerman H, Kloner RA, Briggs LL, Braunwald E. Enhancement of salvage of reperfused myocardium by early β -adrenergic blockade. J Am Coll Cardiol. 3:1984;1438-1443.
12. Steurer G, Yang P, Rao V, Mohl W, Glogar D, Smetana R. Acute myocardial infarction, reperfusion injury, and intravenous magnesium therapy. Basic concepts and clinical implications. Am Heart J. 132:((Suppl 2)):1996;478-482.
13. Simpson PJ, Mickelson J, Fantone JC, Gallagher KP, Lucchesi BR. Iloprost inhibits neutrophil function in vitro and in vivo and limits experimental infarct size in canine heart. Circ Res. 60:1987;666-673.
14. Schaer GL, Hursey TL, Abrahams SL, Buddemeier K, Ennis B, Rodriguez ER, Hubbell JP, Moy J, Parrillo JE. Reduction in reperfusion-induced myocardial necrosis in dogs by RheothRx injection (poloxamer 188 N.F.), a hemorrheological agent that alters neutrophil function. Circulation. 90:1994;2964-2975.
15. Noble MI, Belcher PR, Drake-Holland AJ. Limitation of infarct size by trimetazidine in the rabbit. Am J Cardiol. 76:((suppl)):1995;41B-44B.
16. Silver MJ, Sutton JM, Hook S, Lee P, Malycky JL, Phillips ML, Ellis SG, Topol EJ, Nicolini FA. Adjunctive selectin blockade successfully reduces infarct size beyond thrombolysis in the electrolytic canine coronary artery model. Circulation. 92:1995;492-499.
17. Olafsson B, Forman MB, Puett DW, Pou A, Cates CU, Friesinger GC, Virmani R. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow pheonomenon. Circulation. 76:1987;1135-1145.
18. Babbitt DG, Bermani R, Forman MB. Intracoronary adenosine administered after reperfusion limits vascular injury after prolonged ischemia in the canine model. Circulation. 80:1989;1388-1399.
19. Babbitt DG, Virmani R, Vildibill HD, Norton ED, Forman MB. Intracoronary adenosine administration during reperfusion following 3 hours of ischemia: effects on infarct size, ventricular function, and regional myocardial blood flow. Am Heart J. 120:1990;808-818.
20. Homeister JW, Hoff PT, Fletcher DD, Lucchesi BR. Combined adenosine and lidocaine administration limits myocardial reperfusion injury. Circulation. 82:1990;595-608.
21. Pitarys CJ, Virmani R, Vildibill HD, Jackson EK, Forman MB. Reduction of myocardial reperfusion injury by intravenous adenosine administered during the early reperfusion period. Circulation. 83:1991;237-247.
22. Velasco EC, Turner M, Cobb MA, Virmani R, Forman MB. Myocardial reperfusion injury in the canine model after 40 minutes of ischemia: effect of intracoronary adenosine. Am Heart J. 122:1991;1561-1570.
23. Granger CB, White H, Bates E, Ohman EM, Califf RM. A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. Am J Cardiol. 74:1994;1220-1228.
24. Harrison JK, Califf RM, Woodlief LH, Kereiakes D, George BS, Stack RS, Ellis SG, Lee KL, O'Neill W, Topol EJ. Systolic left ventricular function after reperfusion therapy for acute myocardial infarction: an analysis of determinants of improvement. Circulation. 87:1993;1531-1541.
25. Honan MB, Harrell FE, Reimer KA, Califf RM, Mark DB, Pryor DB, Hlatky MA. Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. J Am Coll Cardiol. 16:1990;359-367.
26. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 329:93;673-682.
27. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 329:93;1615-1622.
28. Kleiman NS, White HD, Ohman EM, Ross AM, Woodlief LH, Califf RM, Holmes DR Jr, Bates E, Pfisterer M, Vahanian A, Topol EJ. Mortality within 24 hours of thrombolysis for myocardial infarction: The importance of early reperfusion. Circulation. 90:1994;2658-2665.
29. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med. 320:89;618-627.
30. Topol EJ, Ellis SG, Califf RM, George BS, Stump DC, Bates ER, Nabel EG, Walton JA, Candela RJ, Lee KL, Kline EM, Pitt B. Combined tissue-type plasminogen activator and prostacyclin therapy for acute myocardial infarction. J Am Coll Cardiol. 14:1989;877-884.
31. Wall TC, Califf RM, Blankenship J, Talley JD, Tannenbaum M, Schwaiger M, Gacioch G, Cohen MD, Sanz M, Leimberger JD, Topol EJ. Intravenous Fluosol in the treatment of acute myocardial infarction. Results of the Thrombolysis and Angioplasty in Myocardial Infarction 9 Trial. Circulation. 90:1994;114-120.
32. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulfate in 58,050 patients with suspected acute myocardial infarction. Lancet. 345:95;669-685.
33. CORE Trial Preliminary Results, presented at the American Heart Association 68th Scientific Sessions, November, 1995.
34. EMIP-FR Preliminary Results. May 1996.
35. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis. 27:1985;335-371.
36. Flemming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med. 125:1996;605-613.
37. Ely SW, Berne RM. Protective effects of adenosine in myocardial ischemia. Circulation. 85:1992;893-904.
38. Forman MB, Velasco CE, Jackson EK. Adenosine attenuates reperfusion injury following regional myocardial ischemia. Cardiovasc Res. 27:1993;9-17.
39. Mauser M, Hoffmeister HM, Nienaber C, Schaper W. Influence of ribose, adenosine, and "AICAR" on the rate of myocardial adenosine triphosphate synthesis during reperfusion after coronary artery occlusion in the dog. Circ Res. 56:1985;220-230.
40. Richardt G, Wass W, Kranzhofer R, Mayer E, Schomig A. Adenosine inhibits exocytotic release of endogenous noradrenaline in rat heart: a protective mechanism in early myocardial ischemia. Circ Res. 61:1987;117-123.
41. Cronstein BN, Kramer SB, Weissmann G, Hirschhorn R. Adenosine: a physiologic modulator of superoxide anion generation by human neutrophils. J Exp Med. 158:1983;1160-1177.
42. 2 activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. Circulation. 92:((suppl I)):1995;I-524.
43. Cronstein BN, Levin RI, Belanoff J, Weissmann G, Hirschhorn R. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest. 78:1986;760-770.
44. Alexander JH, Granger CB, Thompson RD, Sadowski Z, Aylward PE. Prophylactic lidocaine use in GUSTO-I and GUSTO-II: incidence and clinical outcomes. Circulation. 94:((Suppl I)):1996;I-97.
45. Mobarek S, Moreno CA, Revall S, Barbee RW, Murgo JP, Cheirif J. Adenosine reduces micro-vascular damage in the post-infarction period: a myocardial contrast echocardiography study. (Abstr.)J Am Coll Cardiol. 28:1996;406A.
46. Yao Z, Gross GJ. A comparison of adenosine-induced cardioprotection and ischemic preconditioning in dogs. Efficacy, time course, and role of K-ATP channels. Circulation. 89:1994;1229-1236.
47. Kitakaze M, Hori M, Morioka T, Minamino T, Takashima S, Sato H, Shinozaki Y, Chujo M, Mori H, Inoue M, Kamada T. Infarct size-limiting effect of ischemic preconditioning is blunted by inhibition of 5′-nucleotidase activity and attenuation of adenosine release. Circulation. 89:1994;1237-1246.
48. 1 adenosine receptors in rabbit heart. Circulation. 84:1991;350-356.
49. 2 receptor activation. Circulation. 92:((suppl I)):1995;I-524.
50. Garratt KN, Gibbons RJ, Reeder GS, Laudon DA, Lobl JK, Holmes DR. Intravenous adenosine and lidocaine to limit reperfusion injury during acute myocardial infarction: preliminary data. (Abstr.) J Am Coll Cardiol. 25:((suppl)):1995;104A.
51. Marzilli M, Marraccini P, Gliozheni E, Orsini E, Picano E. Intracoronary adenosine as an adjunct to combined use of primary angioplasty in acute myocardial infarction: beneficial effects on angiographically assessed no-reflow. (Abstr.) J Am Coll Cardiol. 28:((suppl)):1996;406A.
52. Lincoff AM, Topol EJ. Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction? Circulation. 88:1993;1361-1374.
53. Leesar M, Ahmed M, Broadbent J, Prince C, Stoddard M, Bolli R. Adenosine preconditions human myocardium during PTCA. (Abstr.) J Am Coll Cardiol. 27:1996;(suppl)30A.
54. Mentzer RM Jr, Conver CC, Chopra PS, Lover RV, Rahko PS, Hegge JO, Lasley RD. Effcacy of adenosine as an additive to blood cardioplegia in humans during open-heart surgery. Circulation. 92:((suppl I)):1995;I-762.
55. Gibbons RJ, Christian TF, Hopfenspirger M, Hodge DO, Bailey KR. Myocardium at risk and infarct size after thrombolytic therapy for acute myocardial infarction: implications for the design of randomized trials of acute myocardial intervention. J Am Coll Cardiol. 24:1994;616-623.